Transdermal estrogens in the changing landscape of hormone replacement therapy

References

• Ettinger B, Wang SM, Leslie RS, et al. Evolution of postmenopausal hormone therapy between 2002 and 2009. Menopause. 2012;19:610–615.
   PubMed Web of Science ®Google Scholar
• Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA. 2004;291:47–53.
   PubMed Web of Science ®Google Scholar
• Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016–1037.
   PubMed Web of Science ®Google Scholar
• Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321–333.
   PubMed Web of Science ®Google Scholar
• Stampfer MJ, Willett WC, Coldiz GA, et al. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med. 1985;313:1044–1049.
   PubMed Web of Science ®Google Scholar
• Henderson BE, Paganini-Hill A, Ross RK. Estrogen replacement therapy and protection from acute myocardial infarction. Am J Obstet Gynecol. 1988;159:312–317.
   PubMed Web of Science ®Google Scholar
• Humphrey LL, Benjamin KS, Sox HC. Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Intern Med. 2002;137:273–284.
   PubMed Web of Science ®Google Scholar
• Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and estrogen/progestin replacement study follow-up in (HERS II). JAMA. 2002;288:49–57.
   PubMed Web of Science ®Google Scholar
• Grodstein F, Stampfer MJ, Manson JE, et al. Post-menopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 1996;335:453–461.
   PubMed Web of Science ®Google Scholar
• Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA. 2004;291:1701–1712.
   PubMed Web of Science ®Google Scholar
• Haas JS, Kaplan CP, Gerstenberger EP, et al. Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med. 2004;140:184–188.
   PubMed Web of Science ®Google Scholar
• Majumdar SR, Almasi EA, Stafford RS. Promotion and prescribing of hormone therapy after report of harm by the Women’s Health Initiative. JAMA. 2004;292:1983–1988.
   PubMed Web of Science ®Google Scholar
• Stephenson J. FDA orders estrogen safety warnings: agency offers guidelines for HRT use. JAMA. 2003;289:537–538.
   PubMed Web of Science ®Google Scholar
• ACOG Task Force on Hormone Therapy. Hormone therapy. Obstet Gynecol. 2004;104:1s–131s.
   PubMed Web of Science ®Google Scholar
• Goodman MP. Are all estrogens created equal? A review of oral vs. transdermal therapy. J Women’s Health. 2012;21:161–169.
   PubMed Web of Science ®Google Scholar
• Stuenkel CA. Menopausal hormone therapy. Endocrin Metab Clin N Am. 2015;44:565–585.
   PubMed Web of Science ®Google Scholar
• ACOG practice bulletin number 141. Management of menopausal symptoms. Obstet Gynecol. 2014;123:202–216.
   PubMed Web of Science ®Google Scholar
• Baber RJ, Panay N, Fenton A. The IMS Writing Group, 2016 IMS recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19:109–150.
   PubMed Web of Science ®Google Scholar
• Gleason CE, Carlsson CM, Johnson S, et al. Clinical pharmacology and differential cognitive efficacy of estrogen preparations. Ann NY Acad Sci. 2005;1052:93–115.
   PubMed Web of Science ®Google Scholar
• Campagnoli C, Biglia N, Altare F, et al. Differential effects of oral conjugated estrogens and transdermal estradiol on insulin-like growth factor 1, growth hormone and sex hormone binding globulin serum levels: matrix versus reservoir patches. Gynecol Endocrinol. 1993;7:251–258.
   PubMed Web of Science ®Google Scholar
• Margarido PF, Bagnoli VR, Maggio Da Fonseca A, et al. Transdermal estrogen therapy effects on fibrinogen levels in women with a past history of venous thromboembolism: a pilot study. Cin Exp Obstet Gynecol. 2011;38:232–235.
   PubMed Web of Science ®Google Scholar
• Post MS, Christella M, Thomassen LG, et al. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women. Arterioscler Thromb Vasc Biol. 2003;23:1116–1121.
   PubMed Web of Science ®Google Scholar
• Bonduki CE, Lourenco DM, Motta EL, et al. Effect of estrogen-progestin hormonal replacement therapy on blood coagulation and fibrinolysis in postmenopausal women. Clinics (Sao Paulo). 2007;62:553–560.
   PubMed Web of Science ®Google Scholar
• Mohammed K, Moain A, Dabrh A, et al. Oral vs transdermal estrogen therapy and vascular events: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2015;100:4012–4020.
   PubMed Web of Science ®Google Scholar
• Corbelli H, Shaikh N, Wessel C, et al. Low-dose transdermal estradiol for vasomotor symptoms: a systematic review. Menopause. 2015;22:114–121.
   PubMed Web of Science ®Google Scholar
• Liu B. Is transdermal menopausal hormone therapy a safer option than oral therapy? Cmaj. 2013;185:549–550.
   PubMed Web of Science ®Google Scholar
• Kapp N. WHO provider brief on hormonal contraception and liver disease. Contraception. 2009 [Accessed May 152017.];80:325–326.
   PubMed Web of Science ®Google Scholar
• Samsioe G. Transdermal hormone therapy; gels and patches. Climacteric. 2004;7:347–356.
   PubMed Web of Science ®Google Scholar
• Musel AL, Warshaw EM. Cutaneous reactions to transdermal therapeutic systems. Dermatitis. 2006;17:109–122.
   PubMed Web of Science ®Google Scholar
• Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric. 2005;8:3–63.
   PubMed Web of Science ®Google Scholar
• Erianne JA, Winter L Jr. Comparison of local tolerability and adhesion of a new matrix system (Menorest) for estradiol delivery with and established transdermal membrane systems (Estraderm TTS). Maturitas. 1997;26:95–101.
   PubMed Web of Science ®Google Scholar
• Reginster JY, Donazzolo Y, Brion N, et al. Estradiol pharmacokinetics after transdermal application of patches to post-menopausal women: matrix versus reservoir patches. Climacteric. 2000;3:168–175.
   PubMedGoogle Scholar
• Munoz A. Oesclim: an advanced delivery system for HRT. Maturitas. 1999;33:S39–S47.
   PubMed Web of Science ®Google Scholar
• Rozenbaum H, Birkhauser M, De Nooyer C, et al. Comparison of two estradiol transdermal Systems (Oesclim 50 and Estraderm TTS 50). Tolerability, adhesion and efficacy. Maturitas. 1996;25:161–173.
   PubMed Web of Science ®Google Scholar
• Kopper NW, Gudeman J, Thompson DJ. Transdermal hormone therapy in postmenopausal women: a review of metabolic effects and drug delivery technologies. Drug Des Devel Ther. 2009;2:193–202.
   PubMedGoogle Scholar
• Abdi F, Mobedi H, Mosaffa N, et al. Hormone therapy for relieving postmenopausal vasomotor symptoms: a systematic review. Arch Iranian Med. 2016;19:141–146.
   PubMed Web of Science ®Google Scholar
• Paudel KS, Milewksi M, Swadley CL, et al. Challenges and opportunities in dermal/transdermal delivery. Ther Deliver. 2010;1:109–131.
   PubMedGoogle Scholar
• Pharmacist Letter. Postmenopausal hormone therapy. Stockton, CA: Therapeutic Research Center. March, 2014.
   Google Scholar
• Estradiol. Index Nominum. 2014;1:717–723. Accessed March 3, 2017.
   Google Scholar
• Moyer V. On behalf of the US Preventative Task Force, Menopausal hormone therapy for the prevention of chronic conditions: US preventative task force recommendation statement. Ann Intern Med. 2013;158:47–54.
   PubMed Web of Science ®Google Scholar
• O’Connor L. NAMS hormone therapy position statement. OBG Management. 2016;28:10.
   Google Scholar
• Lambrinoudaki I, Brincat M, Tamer Erel C, et al. EMAS position statement: managing obese postmenopausal women. Maturitas. 2010;66:323–326.
   PubMed Web of Science ®Google Scholar
• Brennan JJ, Lu Z, Whtiman M, et al. Gerritsen van der Hoop R. Serum concentration of 17-estradio and estrone after multiple-dose administration of percutaneous estradiol gel in symptomatic menopausal women. Ther Drug Monit. 2001;23:134–138.
   PubMed Web of Science ®Google Scholar
• Natchtigall LE. Emerging delivery systems for estrogen replacement. Aspects of transdermal and oral delivery. Am J Obstet Gynecol. 1995;173:993–997.
   PubMed Web of Science ®Google Scholar
• Baracat EC, Simoes MJ, Soares JM Jr, et al. Rodrigues de Lima G. Ultrastructural aspects of the postmenopausal endometrium after oral or transdermal estrogen administration. Clin Exp Obstet Gynecol. 2001;28:26–30.
   PubMedGoogle Scholar
• L’hermite M, Simoncini T, Fuller S, et al. Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review. Maturitas. 2008;60:185–201.
   PubMed Web of Science ®Google Scholar